Chino Hills, CA, Aug. 09, 2018 (GLOBE NEWSWIRE) -- We are advised by SOHM, Inc. (PINKSHEETS: SHMN) that
journalists and other readers should disregard the news release, "SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute
Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug," issued Thursday, August
9, 2018, over GlobeNewswire.
